Compare HELE & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELE | IMMP |
|---|---|---|
| Founded | 1968 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.1M | 426.9M |
| IPO Year | N/A | N/A |
| Metric | HELE | IMMP |
|---|---|---|
| Price | $17.02 | $2.75 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 788.3K | 182.1K |
| Earning Date | 01-08-2026 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,802,156,000.00 | $3,306,742.00 |
| Revenue This Year | N/A | $292.48 |
| Revenue Next Year | $0.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $16.29 | $1.32 |
| 52 Week High | $60.42 | $3.53 |
| Indicator | HELE | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 46.93 |
| Support Level | $17.95 | $2.56 |
| Resistance Level | $19.44 | $2.83 |
| Average True Range (ATR) | 0.99 | 0.14 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 21.27 | 28.36 |
Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.